GlassScriptPhysician profile
Arun D Mathur
NPI 1376705822
$3,632.57
in general payments reported to CMS, 2019-2025
31 companies · $395 in 2025
The $395 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $948 · 2020: $301 · 2021: $357 · 2022: $564 · 2023: $644 · 2024: $424 · 2025: $395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,462.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $982.20 | 2021-2025 | |
| Novo Nordisk INC | $488.62 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $450.66 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $269.93 | 2019-2024 | Airsupra, Farxiga, Breztri |
| Teva Pharmaceuticals USA, INC. | $136.37 | 2019-2023 | Austedo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.90 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $124.98 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $91.48 | 2019-2022 | |
| Lilly USA, LLC | $90.06 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $86.58 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $85.69 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.86 | 2019-2021 | |
| Exact Sciences Corporation | $74.02 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sumitomo Pharma America, INC. | $65.67 | 2023-2024 | Gemtesa |
| Lundbeck LLC | $52.37 | 2024 | Vyepti, Rexulti |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $52.05 | 2019 | |
| Astellas Pharma US INC | $51.04 | 2019-2020 | |
| Bausch Health US, LLC | $48.91 | 2021-2024 | Aplenzin |
| Allergan, INC. | $36.23 | 2019-2020 | |
| Corcept Therapeutics | $35.39 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.53 | 2020-2021 | |
| Grifols USA, LLC | $24.03 | 2025 | Prolastin-C Liquid |
| Phadia US INC. | $21.19 | 2024 | Immunocap |
| Abbott Laboratories | $18.46 | 2023 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $18.13 | 2021 | |
| Alexion Pharmaceuticals, INC. | $17.84 | 2023 | Ultomiris |
| Biogen, INC. | $17.25 | 2021 | |
| Almatica Pharma LLC | $14.66 | 2022 | |
| Seqirus USA INC | $13.65 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.92 | 2019 | |
| Medline Industries LP | $12.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arun Mathur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.